Cargando…
Phase II study of whole brain radiotherapy with or without erlotinib in patients with multiple brain metastases from lung adenocarcinoma
The aim of this paper is to explore the efficacy of whole brain radiotherapy (WBRT) versus WBRT concurrent with erlotinib in patients with multiple brain metastases of lung adenocarcinoma. WBRT was administered at 30Gy/10f in both arms. In the combination arm, 150 mg erlotinib was given each day, st...
Autores principales: | Zhuang, Hongqing, Yuan, Zhiyong, Wang, Jun, Zhao, Lujun, Pang, Qingsong, Wang, Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3797237/ https://www.ncbi.nlm.nih.gov/pubmed/24133369 http://dx.doi.org/10.2147/DDDT.S53011 |
Ejemplares similares
-
Preliminary analysis of the risk factors for radiation pneumonitis in patients with non-small-cell lung cancer treated with concurrent erlotinib and thoracic radiotherapy
por: Zhuang, Hongqing, et al.
Publicado: (2014) -
Randomized Trial of Erlotinib Plus Whole-Brain Radiotherapy for NSCLC Patients With Multiple Brain Metastases
por: Lee, Siow Ming, et al.
Publicado: (2014) -
MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma
por: Zhuang, Hongqing, et al.
Publicado: (2016) -
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis
por: Zheng, Mao-hua, et al.
Publicado: (2016) -
Whole brain radiotherapy with radiosensitizer for brain metastases
por: Viani, Gustavo Arruda, et al.
Publicado: (2009)